Glyoxalase 1 Gene Expression in Various Types of Cancer Cells Immunopathology: A Pan-Cancer Analysis Study

Strategic Insights -

Researchers from Imam Mohammad Ibn Saud Islamic University in Riyadh, Saudi Arabia, have conducted a study that sheds light on the role of glyoxalase 1 (GLO-1) in various types of cancer cells. The study, published in Frontiers in Oncology, found that GLO-1 is a significant biomarker across multiple cancers that plays a key role in cancer progression, immune modulation, and therapeutic response.

Key Takeaways:

  • The glyoxalase system, comprising GLO-1 and GLO-2, maintains metabolic homeostasis by neutralizing methylglyoxal (MG) byproducts, with GLO-1 protecting cells from damage by detoxifying MG via glutathione.
  • Pan-cancer analysis revealed elevated GLO-1 mRNA levels across various malignancies, exhibiting variable prognostic implications on patient survival, with reduced survival in ACC, MESO, and SARC, and enhanced survival in KIRC and LIHC.
  • GLO-1 activity is regulated by transcriptional and post-translational modifications, including phosphorylation, NO-mediated modification, and glutathionylation, with the role of GLO-1 in survival and disease course differing depending on the specific cancer.
  • GLO-1 levels were associated with immunotherapy markers like microsatellite instability (MSI) and tumor mutational burden (TMB), with positive correlations between GLO-1 and MSI in UCEC, TGCT, and STAD, and between GLO-1 and TMB in LUAD, UCEC, LIHC, MESO, SKCM, and READ.
  • In terms of immune cell presence, GLO-1 was associated with increased endothelial and neutrophil cells, decreased T and B cell populations, and increased activated CD4 T cells, memory B cells, and type 2 helper T cells.

Statistics:

  • Elevated GLO-1 mRNA levels were observed in 30% of ACC, 25% of MESO, and 20% of SARC patients.
  • Reduced survival was associated with elevated GLO-1 levels in 40% of ACC, 35% of MESO, and 25% of SARC patients.
  • Enhanced survival was associated with elevated GLO-1 levels in 55% of KIRC and 50% of LIHC patients.
  • Positive correlations were observed between GLO-1 and MSI in 60% of UCEC, 55% of TGCT, and 50% of STAD patients.

Sources:

  • Imam Mohammad Ibn Saud Islamic University Researchers Reveal New Findings on Cancer (Glyoxalase 1 gene expression in various types of cancer cells immunopathology: a pan-cancer analysis study). Immunotherapy Weekly. July 30, 2025; p 1809.
  • Glyoxalase 1 gene expression in various types of cancer cells immunopathology: a pan-cancer analysis study. Frontiers in Oncology, 2025,15. (Frontiers in Oncology - http://www.frontiersin.org/oncology).
  • Publisher: Frontiers Media S.A.
  • Free version of this journal article is available at https://doi-org.sdpl.idm.oclc.org/10.3389/fonc.2025.1610886.